Date: 2012-06-18
Type of information: R&D agreement
Compound:
Company: GSK (UK) University of Cambridge (UK)
Therapeutic area:
Type agreement: R&D
Action mechanism:
Disease:
Details: The University of Cambridge has launched an open innovation drug discovery initiative with GSK. The two partners will embark on a programme of scientific open collaboration that will involve working alongside GSK scientists and other partner organisations, to advance drug discovery and the development of new medicines.
Researchers will be based at Stevenage Bioscience Catalyst (SBC), the UK’s first open innovation bioscience campus, co-located with GSK’s Research and Development centre. This bioscience park provides an independent scientific community allowing scientists to foster relationships across organisations and share their expertise and knowledge. Small teams of Cambridge scientists will bring their world-leading medical and biological research to this open innovation environment and have already committed to working alongside GSK drug development experts who will provide access to their drug discovery and development expertise.
Cambridge Enterprise, the University’s commercialisation arm, will facilitate the programme. A key element of the open innovation environment fostered through the bioscience park is enabling scientific exchange to flourish without the need for exclusive research collaboration agreements between partners, including GSK. The open innovation model allows Cambridge scientists to freely interact with other pharmaceutical biotech, contract research organisations, SBC tenants and academic institutions.
Financial terms:
Latest news:
